13 papers · ranked by Valyu relevance
Latent Labs Team, Henry Kenlay, Daniella Pretorius, Jonathan Crabbé + 14 more
Drug discovery has long sought computational systems capable of designing drug-like molecules directly: developable and nonimmunogenic from the start. Here we introduce Latent-X2, a frontier generative model that achieves this goal through zero-shot design of antibodies with strong binding affinities, drug-like…
Zhao, Siqi, Moller, Joshua + 4 more
Therapeutic antibodies require not only highaffinity target engagement, but also favorable manufacturability, stability, and safety profiles for clinical effectiveness. These properties are collectively called 'developability'. To enable a computational framework for optimizing antibody sequences for favorable…
Asif Khan, Alexander I. Cowen-Rivers, Derrick-Goh-Xin Deik, Antoine Grosnit + 10 more
'Antoine Grosnit' 'Philippe A. Robert' 'Victor Greiff' 'Eva Smorodina' 'Puneet Rawat' 'Rahmad Akbar' 'Kamil Dreczkowski' 'Rasul Tatunov' 'Dany Bou-Ammar' 'Jun Wang' 'Haitham Bou Ammar'] Antibodies are canonically Y-shaped multimeric proteins capable of highly specific molecular recognition. The CDRH3 region located at…
Matthew Greenig, Haowen Zhao, Vladimir Radenkovic, Aubin Ramon + 1 more
'Pietro Sormanni'] Designing antibody sequences to better resemble those observed in natural human repertoires is a key challenge in biologics development. We introduce IgCraft: a multi-purpose model for paired human antibody sequence generation, built on Bayesian Flow Networks. IgCraft presents one of the first…
Andreas Evers, Shipra Malhotra, Vanita D. Sood
The recognition of the importance of drug-like properties beyond potency to reduce clinical attrition of biologics has driven significant progress in the development of in vitro and in silico tools for developability assessment of antibody sequences. It is now routine to identify and eliminate or optimize antibody hits…
Weronika Bielska, Igor Jaszczyszyn, Pawel Dudzic, Bartosz Janusz + 6 more
'Dawid Chomicz' 'Sonia Wrobel' 'Victor Greiff' 'Ryan Feehan' 'Jared Adolf-Bryfogle' 'Konrad Krawczyk'] Abstract: Machine learning applications in protein sciences have ushered in a new era for designing molecules in silico. Antibodies, which currently form the largest group of biologics in clinical use, stand to…
Zhao, Xinyan, Tang, Yi-Ching + 20 more
We introduce AbBiBench (Antibody Binding Benchmarking), a benchmarking framework for antibody binding affinity maturation and design. Unlike previous strategies that evaluate antibodies in isolation, typically by comparing them to natural sequences with metrics such as amino acid recovery rate or structural RMSD…
Lin Li, Esther Gupta, John Spaeth, Leslie Shing + 2 more
'Rajmonda S. Caceres'] Therapeutic antibody development has become an increasingly popular approach for drug development. To date, antibody therapeutics are largely developed using large scale experimental screens of antibody libraries containing hundreds of millions of antibody sequences. The high cost and difficulty…
Paul Pereira, Hervé Minoux, Aleksandra M. Walczak, Thierry Mora
Since the approval of the first antibody drug in 1986, a total of 162 antibodies have been approved for a wide range of therapeutic areas, including cancer, autoimmune, infectious, or cardiovascular diseases. Despite advances in biotechnology that accelerated the development of antibody drugs, the drug discovery…
Cheng Tan, Yijie Zhang, Zhangyang Gao, Yufei Huang + 5 more
'Lirong Wu' 'Fandi Wu' 'Mathieu Blanchette' 'Stan. Z. Li'] The development of therapeutic antibodies heavily relies on accurate predictions of how antigens will interact with antibodies. Existing computational methods in antibody design often overlook crucial conformational changes that antigens undergo during the…
Bruna Silva, David B. Ascher, Nicholas Geard, Douglas E. V. Pires
Systems and Computational Biology, Bio21 Institute, University of Melbourne,Melbourne, Victoria, Australia Computational Biology and Clinical Informatics, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia School of Computing and Information Systems, University of Melbourne, Melbourne, Victoria…
Maria Francesca Abbate, Pierre Toxe, Nicolas Maestrali, Marie Gagnaire + 4 more
The identification and validation of therapeutic antibodies is critical for developing effective treatments for many diseases. We present a computational approach for identifying antibodies targeting GFRAL-specific receptors, receptors implicated in appetite regulation. Using humanized Trianni mice, we conducted a…
Hirofumi Tsuruta, Hiroyuki Yamazaki, Ryota Maeda, Ryotaro Tamura + 7 more
'Jennifer N. Wei' 'Zelda Mariet' 'Poomarin Phloyphisut' 'Hidetoshi Shimokawa' 'Joseph R. Ledsam' 'Lucy J. Colwell' 'Akihiro Imura'] Antibodies have become an important class of therapeutic agents to treat human diseases. To accelerate therapeutic antibody discovery, computational methods, especially machine learning…